Technical Analysis for GLSI - Greenwich LifeSciences, Inc.

Grade Last Price % Change Price Change
D 36.5 -0.54% -0.20
GLSI closed down 0.54 percent on Friday, January 22, 2021, on 17 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Very Strong N/A Up Flat
Historical GLSI trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
20 DMA Support Bullish -0.54%
1,2,3 Pullback Bullish Bullish Swing Setup -0.54%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.54%
Narrow Range Bar Range Contraction -0.54%
20 DMA Support Bullish -2.14%
Older End-of-Day Signals for GLSI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Greenwich LifeSciences, Inc. Description

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Acid Surgery Immunotherapy Cancer Treatments Breast Cancer Treatment Of Breast Cancer Clinical Trial Greenwich Her2 Cancer Center Her2/Neu

Is GLSI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 158.07
52 Week Low 3.262
Average Volume 1,000,781
200-Day Moving Average 0.00
50-Day Moving Average 26.47
20-Day Moving Average 36.62
10-Day Moving Average 36.57
Average True Range 5.50
ADX 51.36
+DI 41.41
-DI 13.17
Chandelier Exit (Long, 3 ATRs ) 28.94
Chandelier Exit (Short, 3 ATRs ) 49.73
Upper Bollinger Band 39.42
Lower Bollinger Band 33.82
Percent B (%b) 0.48
BandWidth 15.28
MACD Line 2.00
MACD Signal Line 2.84
MACD Histogram -0.8416
Fundamentals Value
Market Cap 438.7 Million
Num Shares 12 Million
EPS
Price-to-Sales 0.00
Price-to-Book 14.14
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 39.51
Resistance 3 (R3) 39.53 38.54 39.01
Resistance 2 (R2) 38.54 37.77 38.53 38.84
Resistance 1 (R1) 37.52 37.30 37.03 37.50 38.68
Pivot Point 36.53 36.53 36.28 36.52 36.53
Support 1 (S1) 35.51 35.76 35.02 35.50 34.32
Support 2 (S2) 34.52 35.29 34.51 34.16
Support 3 (S3) 33.50 34.52 33.99
Support 4 (S4) 33.49